

Budiodarone tartrate

Chemical Properties

CAS No. : 478941-93-4


Formula: C₃₁H₃₇I₂N₂O₁₁

Molecular Weight: 853.44

Keep away from direct sunlight, Keep away from moisture

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Budiodarone tartrate (ATI-2042 tartrate) is a chemical analog of Amiodarone, an antiarrhythmic drug that inhibits sodium, potassium, and calcium ion channels. It is used for studying atrial fibrillation.
Targets(IC50)	Calcium Channel, Potassium Channel, Sodium Channel
In vitro	Budiodarone tartrate has a short half-life in plasma (7 hours) and a small volume of distribution (13 L/kg). [1]

Solubility Information

Solubility	DMSO: 80 mg/mL (93.74 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.34 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1717 mL	5.8586 mL	11.7173 mL
5 mM	0.2343 mL	1.1717 mL	2.3435 mL
10 mM	0.1172 mL	0.5859 mL	1.1717 mL
50 mM	0.0234 mL	0.1172 mL	0.2343 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ezekowitz MD, et al. A randomized trial of bupropion in paroxysmal atrial fibrillation. *J Interv Card Electrophysiol.* 2012 Jun;34(1):1-9.

Arya A, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. *Europace.* 2009 Apr;11(4):458-64.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481